Multifocal Motor Neuropathy – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033 thelansis.com

Multifocal motor neuropathy (MMN), also known as multifocal motor neuropathy with conduction block (MMNCB), is a rare and acquired form of motor neuropathy characterized by progressive asymmetric weakness without sensory involvement. Immune-mediated mechanisms are believed to be the underlying cause of the disease, as evidenced by the high prevalence of serum IgM anti-GM1 antibodies in affected individuals and the favorable response to treatment with intravenous immunoglobulin (IVIG). The concentration of GM1, a ganglioside found in the myelin of motor nerves, is higher in motor nerves than in sensory nerves, which may explain the selective motor involvement in MMN. The conduction block seen in electrophysiological studies in MMN is thought to be caused by anti-GM1 antibodies, which disrupt the function of sodium and potassium channels at the nodes of Ranvier, leading to decreased action potential propagation and reduced conduction velocity. Differential diagnoses of MMN include ALS, CIDP, and hereditary neuropathy with liability to pressure palsies (HNPP), radiculopathy, entrapment neuropathies, mononeuritis multiplex, hereditary motor neuropathies, porphyria, and lead intoxication. The primary pharmacological treatment option for MMNCB is intravenous immunoglobulin (IVIG), with a response rate of approximately 80%. In non-responders, treatment options are limited. The prognosis of MMN is generally good, with most patients being able to perform activities of daily living and remaining employed. The disease is rarely fatal due to the sparing of cranial and respiratory muscles. Complications of treatment, such as thromboembolic events, renal failure, anaphylactic reactions, and aseptic meningitis, may occur.
• In the USA and Japan, the prevalence of multifocal motor neuropathy ranges between 0.35 to 0.65 cases per 100,000 population. It affects more males than females, and onset usually occurs before 50 years of age.

Thelansis’s “Multifocal Motor Neuropathy Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033″ covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Multifocal Motor Neuropathy treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights of Multifocal Motor Neuropathy across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.
Multifocal Motor Neuropathy Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.
Read more: Multifocal Motor Neuropathy – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033